Trending...
- Constant Contact Appoints Russ Morton as Chief Product Officer
- CreateTV.com's New Chefs' Indian and Cuban Recipes will Spice Up Your Meals!
- UPS Launches Services at Neighborhood Parcel Authorized Shipping Center In Tewksbury MA
BOSTON, Jan. 24, 2023 /PRNewswire/ -- NanoMosaic, the pioneer and leader of nanoneedle technology (MosaicNeedle™) for proteomics and multiomics, announced the establishment of Scientific Advisory Board (SAB) to support NanoMosaic's vision to bring the nanoneedle-powered digital proteomic tool to the life science research and the diagnostic community. Abhishek Chatterjee, Ph.D. joins NanoMosaic SAB.
Dr. Abhishek Chatterjee is Professor of Chemistry at Boston College. Dr. Chatterjee's lab combines elements of chemical biology, synthetic biology and virology to develop new strategies for understanding and manipulating biological processes in mammalian cells. Dr. Chatterjee has developed various novel genetic code expansion tools to allow site-specific incorporation of enabling noncanonical amino acids into proteins in vivo. Dr. Chatterjee is also co-founder, senior advisor and Chair of Scientific Advisory Board of BrickBio Inc.
"NanoMosaic's powerful MosaicNeedle™ technology has the potential to revolutionize the world of protein detection and quantification. With its great sensitivity over an exceptionally broad dynamic range, as well as its high throughput, it has opened the door to endless possibilities in this field", said Dr. Chatterjee, "I am thrilled to join the NanoMosaic SAB and help this talented team to explore the full potential of this groundbreaking technology" Dr. Chatterjee concluded.
More on Boston Chron
"We are truly thrilled to have Abhishek on NanoMosaic SAB. His seminal work has led to precise, stable and highly efficient site-control of conjugation that unleashes the most optimal function of diagnostic and therapeutic molecules," said Dr. Qimin Quan, Co-Founder, CSO and Chair of SAB of NanoMosaic. "Enabling site-specific conjugation capabilities on the NanoMosaic Tessie™ platform will bring the performance and consistency of diagnostic assays to the next level" Quan concluded.
"Abhishek adds significant value to NanoMosaic, as the company embarks on developing next-generation probes, with novel scaffold and capture mechanisms, for nucleic acids and proteins," stated John Boyce, President, CEO, and Co-Founder of NanoMosaic, as well as Co-Founder of Tiger Gene, LLC. "These novel capture and interrogation methodologies, that work exclusively with nanoneedles will significantly benefit both the research and diagnostic endeavors of scientists and physicians" Boyce concluded.
On June 3rd 2022, NanoMosaic announced partnership with BrickBio to introduce site-specific, stable conjugation to the antibodies for the NanoMosaic CDx neurology panel. The novel antibody has been designed to have higher affinities and enhanced performance on NanoMosaic Tessie™ platform.
More on Boston Chron
About NanoMosaic Inc
NanoMosaic, a Boston-based biotechnology company, is the only commercial entity to develop and leverage the power of nanoneedles, MosaicNeedles™, for protein detection and quantification to develop best-in-class assays for biomarker discovery and validation. The NanoMosaic platform, Tessie™, alleviates the bottlenecks in proteomics analysis and provides an end-to-end solution that enables first of its kind protein interrogation and multi-omics analysis within a single chip on one run. The proprietary technology enables rapid, end user customization for assay development for proteomic and/or nucleic acid content. The NanoMosaic platform allows researchers to push the frontiers in biomarker discovery and diagnostics.
www.nanomosaic.net
CONTACT:
[email protected]
SOURCE NanoMosaic
Dr. Abhishek Chatterjee is Professor of Chemistry at Boston College. Dr. Chatterjee's lab combines elements of chemical biology, synthetic biology and virology to develop new strategies for understanding and manipulating biological processes in mammalian cells. Dr. Chatterjee has developed various novel genetic code expansion tools to allow site-specific incorporation of enabling noncanonical amino acids into proteins in vivo. Dr. Chatterjee is also co-founder, senior advisor and Chair of Scientific Advisory Board of BrickBio Inc.
"NanoMosaic's powerful MosaicNeedle™ technology has the potential to revolutionize the world of protein detection and quantification. With its great sensitivity over an exceptionally broad dynamic range, as well as its high throughput, it has opened the door to endless possibilities in this field", said Dr. Chatterjee, "I am thrilled to join the NanoMosaic SAB and help this talented team to explore the full potential of this groundbreaking technology" Dr. Chatterjee concluded.
More on Boston Chron
- Entrinsik Board Announces New CEO
- Work & Mother Announces Collaboration with Jamestown to Provide State-of-the-Art Lactation Suites in Select Commercial Buildings
- Knobull Streamlines Presentation Techniques That Turns Stress Into Enjoyment
- Eddie Turner Ranked #13 On The Power List Of The Top 200 Biggest Voices In Leadership In 2023
- The Data Economics Company and Gordian Knot Strategies Announce Enkrateia Climate Investment Decision Support Platform
"We are truly thrilled to have Abhishek on NanoMosaic SAB. His seminal work has led to precise, stable and highly efficient site-control of conjugation that unleashes the most optimal function of diagnostic and therapeutic molecules," said Dr. Qimin Quan, Co-Founder, CSO and Chair of SAB of NanoMosaic. "Enabling site-specific conjugation capabilities on the NanoMosaic Tessie™ platform will bring the performance and consistency of diagnostic assays to the next level" Quan concluded.
"Abhishek adds significant value to NanoMosaic, as the company embarks on developing next-generation probes, with novel scaffold and capture mechanisms, for nucleic acids and proteins," stated John Boyce, President, CEO, and Co-Founder of NanoMosaic, as well as Co-Founder of Tiger Gene, LLC. "These novel capture and interrogation methodologies, that work exclusively with nanoneedles will significantly benefit both the research and diagnostic endeavors of scientists and physicians" Boyce concluded.
On June 3rd 2022, NanoMosaic announced partnership with BrickBio to introduce site-specific, stable conjugation to the antibodies for the NanoMosaic CDx neurology panel. The novel antibody has been designed to have higher affinities and enhanced performance on NanoMosaic Tessie™ platform.
More on Boston Chron
- Best Pneumatic Air Jack for Cars (2023): VEVOR 5T Bag Air Jack Reviewed by Compare Before Buying
- Americana Songstress Emma Jo To Release Powerful New Single, 'Straight Into Mine'
- Bain Capital Specialty Finance, Inc. Schedules Earnings Release for the Fourth Quarter and Fiscal Year Ended December 31, 2022
- Boston: Mayor Michelle Wu, Superintendent Mary Skipper and Green New Deal Director Oliver Sellers-Garcia celebrate start of school bus fleet electrification
- IISE announces leadership election results
About NanoMosaic Inc
NanoMosaic, a Boston-based biotechnology company, is the only commercial entity to develop and leverage the power of nanoneedles, MosaicNeedles™, for protein detection and quantification to develop best-in-class assays for biomarker discovery and validation. The NanoMosaic platform, Tessie™, alleviates the bottlenecks in proteomics analysis and provides an end-to-end solution that enables first of its kind protein interrogation and multi-omics analysis within a single chip on one run. The proprietary technology enables rapid, end user customization for assay development for proteomic and/or nucleic acid content. The NanoMosaic platform allows researchers to push the frontiers in biomarker discovery and diagnostics.
www.nanomosaic.net
CONTACT:
[email protected]
SOURCE NanoMosaic
Filed Under: Business
0 Comments
Latest on Boston Chron
- Boston Celtics and Sun Life close out 9th annual Fit to Win youth program with Celtics forward Justin Jackson at trampoline park
- Boston: Fire Prevention Program Manager Certificate
- Boston: Mayor Wu Announces Members of Steering Committee to Advise on Reforms to Article 80 Development Review Process
- Dog Licensing Reminder (and Boston's Most Popular Dog Names!)
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Urban One Inc's Reach Media Announces R&B Superstar Ralph Tresvant of New Edition as Host of "Love and R&B"
- ABP Acquisition to Acquire AlerisLife for $1.31 Per Share
- Berkshire Hills Announces Quarterly Shareholder Dividend
- Louisville Riverport Authority Applies To Include South Central Kentucky In Foreign Trade Zone #29 Service Area
- Santander Bank Raises Its Prime Rate to 7.75%
- Constant Contact Appoints Russ Morton as Chief Product Officer
- IntellaTriage Hires New Director of Clinical Operations
- CyberSaint STRONGER 2023 Conference Call for Speakers is Open!
- Metro Commercial brokers deal for BJ's Wholesale Club in West Palm Beach, FL
- L-Strategies political and business consulting firm launched by partners Angie Wong and Jared Craig with Donna and Stan Fitzgerald
- UPS Launches Services at Neighborhood Parcel Authorized Shipping Center In Tewksbury MA
- Zilker Partners Expands Recruiting and Digital Marketing Services to Keep Pace with Changing Business Climate
- CreateTV.com's New Chefs' Indian and Cuban Recipes will Spice Up Your Meals!
- Dental Tourism is on the Rise and This Dental Hygienist is Providing the Consultations
- Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023